These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 6230936)

  • 1. Eligibility criteria for amniocentesis.
    Vekemans M; Lippman A
    Am J Med Genet; 1984 Feb; 17(2):531-3. PubMed ID: 6230936
    [No Abstract]   [Full Text] [Related]  

  • 2. [Mongolism following omitted amniocentesis].
    Fortschr Med; 1984 Feb; 102(8):68. PubMed ID: 6235162
    [No Abstract]   [Full Text] [Related]  

  • 3. [Technic, indications and risks in genetic amniocentesis during early pregnancy].
    Husslein P; Wagenbichler P
    Wien Med Wochenschr; 1980 Jan; 130(2):93-5. PubMed ID: 6446206
    [No Abstract]   [Full Text] [Related]  

  • 4. [Evaluation of trisomy 21 risk by serial determination of chorionic gonadotrophin hormone and alpha-fetoprotein: results of a national pilot study].
    Aymé S; Aurran Y; Chabal F; Gombert A; Loundou H; Montfort C; Sollier M; Silvestri A
    Contracept Fertil Sex; 1993 Feb; 21(2):133-43. PubMed ID: 7524931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Method of risk assessment affects acceptance rate of amniocentesis.
    de la Vega A; Verdiales M; Leavitt G
    P R Health Sci J; 2002 Sep; 21(3):233-5. PubMed ID: 12243114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of Down syndrome: the Jerusalem experience.
    Bach G; Ben-Neriah Z; Sagi M
    Isr J Med Sci; 1993 Aug; 29(8):468-70. PubMed ID: 7691779
    [No Abstract]   [Full Text] [Related]  

  • 7. Down syndrome screening in Singapore--the effectiveness of a second trimester serum screening policy modelled on 29,360 pregnancies in KK Women's and Children's Hospital.
    Lai FM; Yeo GS
    Singapore Med J; 1998 Feb; 39(2):69-75. PubMed ID: 9652180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cost-benefit analysis of prenatal screening for trisomy 21 through analysis of HCG in maternal blood].
    Seror V; Moatti JP; Muller F; Le Galès C; Boué A
    Rev Epidemiol Sante Publique; 1993; 41(1):3-15. PubMed ID: 8465062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down syndrome prevention program in a population with an older maternal age.
    Shohat M; Legum C; Romem Y; Borochowitz Z; Bach G; Goldman B
    Obstet Gynecol; 1995 Mar; 85(3):368-73. PubMed ID: 7862374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Controversy: systemic amniocentesis for women 38 years and more? Is it not premature to no longer accept performing amniocentesis on a patient age 38 years or more?].
    Sagot P
    Gynecol Obstet Fertil; 2000 Oct; 28(10):769-71. PubMed ID: 11270348
    [No Abstract]   [Full Text] [Related]  

  • 11. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol.
    Cheng EY; Luthy DA; Zebelman AM; Williams MA; Lieppman RE; Hickok DE
    Obstet Gynecol; 1993 Jan; 81(1):72-7. PubMed ID: 7677967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Screening for Down's syndrome in the 2d trimester of pregnancy: initial results].
    Stejskal D
    Cesk Gynekol; 1993 Feb; 58(1):5-10. PubMed ID: 8319282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Blood screening for Down's syndrome in women under 35 years of age with an age-independent index].
    Benz R; Müller U; Krahner-Pilat M; Wagner-Geuder S; Terinde R
    Z Geburtshilfe Perinatol; 1993; 197(5):205-8. PubMed ID: 7505992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prenatal screening for Down syndrome.
    Ogle RF; Chitty LS
    Hosp Med; 1998 Aug; 59(8):632-6. PubMed ID: 9829057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Periodic health examination, 1996 update: 1. Prenatal screening for and diagnosis of Down syndrome. Canadian Task Force on the Periodic Health Examination.
    Dick PT
    CMAJ; 1996 Feb; 154(4):465-79. PubMed ID: 8630836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolving national birth prevalence of Down syndrome in Taiwan. A study on the impact of second-trimester maternal serum screening.
    Jou HJ; Kuo YS; Hsu JJ; Shyu MK; Hsieh TT; Hsieh FJ
    Prenat Diagn; 2005 Aug; 25(8):665-70. PubMed ID: 16049991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down's syndrome, amniocentesis, and abortion: prevention or elimination?
    Smith JD
    Ment Retard; 1981 Feb; 19(1):8-11. PubMed ID: 6454053
    [No Abstract]   [Full Text] [Related]  

  • 18. Fetal cells in maternal blood: a six-fold increase in women who have undergone amniocentesis and carry a fetus with Down syndrome: a multicenter study.
    Falcidia E; Parano E; Grillo A; Pavone P; Takabayashi H; Trifiletti RR; Scollo P; Dallapiccola B; Grammatico P; Novelli A; Paladini D; Monni G; Gulisano A; Scassellati G
    Neuropediatrics; 2004 Dec; 35(6):321-4. PubMed ID: 15627938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening advances and diagnostic choice: the problem of residual risk.
    Henry GP; Britt DW; Evans MI
    Fetal Diagn Ther; 2008; 23(4):308-15. PubMed ID: 18417998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for Down's syndrome. Data do not support study's claim.
    Norgaard-Pedersen B
    BMJ; 2000 Sep; 321(7263):763; author reply 764-5. PubMed ID: 10999925
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.